AI assistant
Jade Biosciences, Inc. — Director's Dealing 2021
Jul 2, 2021
33383_dirs_2021-07-01_4f22b403-891a-4cca-9971-e81ba3fdac35.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-02-01
Reporting Person: Katabi Maha (Director, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-01 | Series A Preferred Stock | $ | A | 1164213 | Acquired | Common Stock (374825) | Indirect | |
| 2021-06-04 | Series A Preferred Stock | $ | A | 8082190 | Acquired | Common Stock (2602112) | Indirect | |
| 2021-06-29 | Stock Option (Right to Buy) | $14 | A | 25000 | Acquired | 2031-06-28 | Common Stock (25000) | Direct |
Footnotes
F1: Each share of Series A Preferred Stock is convertible into shares of the Issuer's Common Stock on a one-for-3.1060103 basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date.
F2: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F3: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his or her proportionate pecuniary interest therein.
F4: This option shall vest and become exercisable in 36 substantially equal monthly installments, with the first installment vesting on July 29, 2021.